Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches
Cancers,
Год журнала:
2025,
Номер
17(2), С. 236 - 236
Опубликована: Янв. 13, 2025
Hepatocellular
carcinoma
(HCC)
is
a
leading
cause
of
cancer-related
mortality
worldwide,
and,
with
only
15-20%
HCC
patients
being
suitable
for
potentially
curative
treatments,
the
vast
majority
ultimately
require
systemic
therapy.
For
decades,
choice
effective
therapy
remained
sparse.
In
recent
years,
after
combination
atezolizumab
and
bevacizumab
demonstrated
superior
overall
survival
over
first-line
standard,
sorafenib,
there
has
been
major
therapeutic
paradigm
shift
to
immunotherapy-based
regimens
HCC.
While
representing
great
leap
forward
treatment
this
cancer,
reality
that
less
than
one-third
achieve
an
objective
response
immune
checkpoint
inhibitor-based
therapy,
so
remains
significant
clinical
need
further
optimization.
review,
we
provide
overview
current
landscape
immunotherapy
unresectable
delve
into
tumor
intrinsic
extrinsic
mechanisms
resistance
established
immunotherapies
focus
on
novel
targets
strong
translational
potential.
Following
this,
spotlight
emerging
approaches
notable
trials
aiming
optimize
efficacy
in
include
inhibitors,
microenvironment
modulators,
targeted
delivery
systems,
locoregional
interventions.
Язык: Английский
Integrated singlecell and bulk RNA-seq analysis identifies a prognostic signature related to inflammation in colorectal cancer
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Янв. 6, 2025
Inflammation
can
influence
the
development
of
CRC
as
well
immunotherapy
and
plays
a
key
role
in
CRC.
Therefore,
this
study
aimed
to
investigate
potential
inflammation-related
genes
risk
prediction.
gene
models
were
constructed
validated
by
combining
transcriptomic
single-cell
data
from
TCGA
GEO
databases,
expression
was
verified
RT-qPCR.
We
identified
two
molecular
subtypes
three
genetic
subtypes,
subgroups
according
median
values,
prognostic
model
including
thirteen
(TIMP1,
GDF15,
UCN,
KRT4,
POU4F1,
NXPH1,
SIX2,
NPC1L1,
KLK12,
IGFL1,
FOXD1,
ASPG,
CYP4F8),
performance
each
aspect
an
external
database.
Patients
high-risk
group
had
worse
survival
with
reduced
immune
cell
infiltration
greater
tumor
mutational
load.
The
score
correlated
strongly
checkpoints
PD1,
PDL1,
PDL2,
CTLA4,
it
is
possible
that
patients
are
more
sensitive
treatment
involving
checkpoints.
In
data,
GDF15
most
significantly
expressed
cancer
populations.
we
further
their
cells
tissues
using
qPCR.
summary,
developed
marker
associated
inflammatory
provide
new
directions
for
subsequent
studies
help
clinicians
assess
prognosis
develop
personalized
strategies.
Язык: Английский